FDA approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
- Armstrong Medical Limited Recalls AMSORB PLUS PREFILLED G-CAN 1.0L Due to Reduced Gas Flow to Patients During Anesthesia
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals